Comparative Pharmacology
Head-to-head clinical analysis: CARDIOGRAFIN versus OMNIPAQUE 180.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIOGRAFIN versus OMNIPAQUE 180.
CARDIOGRAFIN vs OMNIPAQUE 180
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cardiografin is an ionic, high-osmolar iodinated contrast agent used for radiographic imaging. It enhances contrast by attenuating X-rays, primarily due to the iodine content. It distributes in the extracellular space and is excreted unchanged by glomerular filtration.
Iodinated contrast agent that radiates X-rays due to high iodine content, attenuating X-ray beams and enhancing vascular/tissue contrast.
Adult: 50-100 mL of CARDIOGRAFIN (diatrizoate meglumine and diatrizoate sodium) 76% intravenously as a bolus or rapid infusion. For cardiac ventriculography, 40-50 mL into the left ventricle. For coronary arteriography, 5-10 mL selective injection per artery.
Intravenous: 50-200 mL of 180 mgI/mL (9-36 g iodine) administered as a bolus or infusion, depending on imaging procedure and patient size; typical CT dose: 100-150 mL.
None Documented
None Documented
Terminal elimination half-life ~2 hours (normal renal function). May be prolonged to >20 hours in severe renal impairment (e.g., CrCl <30 mL/min).
Terminal elimination half-life: 1-2 hours in patients with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe impairment)
Primarily renal (glomerular filtration) with >90% of dose excreted unchanged in urine within 24 hours; less than 1% biliary/fecal; negligible metabolism.
Renal: >95% unchanged by glomerular filtration within 24 hours; Biliary/Fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent